

# JOURNAL OF HEPATOLOGY

The Home of Liver Research

VOLUME 71, ISSUE 5, PAGES 853–1060

## FROM THE EDITOR'S DESK

### From the Editor's Desk. . .

R. Moreau, R. Bataller, T. Berg, S. Lotersztajn, J. Zucman-Rossi and R. Jalan 853

## EDITORIALS

Treatment of infants with hepatitis B virus: A window of opportunity?

S.C. Ling and D. Mogul 856

Towards a personalized approach to hepatic resection in cirrhotic patients

A. Vitale and P. Majno-Hurst 859

A step forward to accurately predict mortality in cirrhotic patients undergoing elective surgery: The role of the hepatic venous pressure gradient

R. Martin Mateos and H. Maddur 862

Anonymous living donation in liver transplantation: Squaring the circle or condemned to vanish?

C. Duvoux 864

Risk stratification in primary sclerosing cholangitis: It's time to move on from replicating imperfection and break the glass ceiling

P.J. Trivedi 867

## RESEARCH ARTICLES

### Viral Hepatitis

Early initiation of antiviral therapy contributes to a rapid and significant loss of serum HBsAg in infantile-onset hepatitis B

S. Zhu, Y. Dong, L. Wang, W. Liu and P. Zhao 871

High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world

A.B. Pérez, N. Chueca, M. García-Deltoro, A.M. Martínez-Sapiña, M.M. Lara-Pérez, S. García-Bujalance, T. Aldámiz-Echevarría, F.J. Vera-Méndez, J.A. Pineda, M. Casado, J.M. Pascasio, J. Salmerón, J.C. Alados-Arboledas, A. Poyato, F. Téllez, A. Rivero-Juárez, D. Merino, M.J. Vivancos-Gallego, J.M. Rosales-Zábal, F. García and on Behalf of the GEHEP-004 Study Group 876

Elimination of hepatitis C virus has limited impact on the functional and mitochondrial impairment of HCV-specific CD8+ T cell responses

A. Aregay, S. Owusu Sekyere, K. Deterding, K. Port, J. Dietz, C. Berkowski, C. Sarrazin, M.P. Manns, M. Cornberg and H. Wedemeyer 889

Anti-PD-1 blockade with nivolumab with and without therapeutic vaccination for virally suppressed chronic hepatitis B: A pilot study

E. Gane, D.J. Verdon, A.E. Brooks, A. Gaggar, A.H. Nguyen, G.M. Subramanian, C. Schwabe and P.R. Dunbar 908

TLR9 signalling in HCV-associated atypical memory B cells triggers Th1 and rheumatoid factor autoantibody responses

C. Comarmond, V. Lorin, C. Marques, A. Maciejewski-Duval, N. Joher, C. Planchais, M. Touzot, L. Biard, T. Hieu, V. Quiniou, A.-C. Desbois, M. Rosenzweig, D. Klatzmann, P. Cacoub, H. Mouquet and D. Saadoun 908

### Cirrhosis

An ordinal model to predict the risk of symptomatic liver failure in patients with cirrhosis undergoing hepatectomy

M. Prodeau, E. Drumez, A. Duhamel, E. Vibert, O. Farges, G. Lassailly, J.-Y. Mabrut, J. Hardwigsen, J.-M. Régimbeau, O. Soubrane, R. Adam, F.-R. Pruvot and E. Boleslawski 920

O-GlcNAcylation-dependent upregulation of HO1 triggers ammonia-induced oxidative stress and senescence in hepatic encephalopathy

B. Görg, A. Karababa, E. Schütz, M. Paluschinski, A. Schrimpf, A. Shafiqullina, M. Castoldi, H.J. Bidmon and D. Häussinger 930

The prognostic role of hepatic venous pressure gradient in cirrhotic patients undergoing elective extrahepatic surgery

E. Reverter, I. Cirera, A. Albillos, W. Debernardi-Venon, J.G. Abraldes, E. Llop, A. Flores, G. Martínez-Palli, A. Blasi, J. Martínez, F. Turon, J.C. García-Valdecasas, A. Berzigotti, A.M. de Lacy, J. Fuster, V. Hernández-Gea, J. Bosch and J.C. García-Pagán 942

### Transplantation

Donor outcomes in anonymous live liver donation

N. Goldaracena, J. Jung, A.D. Aravinthan, S.E. Abbey, S. Krause, C. Pritlove, J. Lynch, L. Wright, N. Selzner, J. Stunguris, P. Greig, A. Ghanekar, I. McGilvray, G. Sapisochin, V.L. Ng, G. Levy, M. Cattral and D. Grant 951

### Molecular and Cell Biology

The epigenetic regulator SIRT6 protects the liver from alcohol-induced tissue injury by reducing oxidative stress in mice

H.G. Kim, M. Huang, Y. Xin, Y. Zhang, X. Zhang, G. Wang, S. Liu, J. Wan, A.R. Ahmadi, Z. Sun, S. Liangpunsakul, X. Xiong and X.C. Dong 960

Generation of expandable human pluripotent stem cell-derived hepatocyte-like liver organoids

S.J. Mun, J.-S. Ryu, M.-O. Lee, Y.S. Son, S.J. Oh, H.-S. Cho, M.-Y. Son, D.-S. Kim, S.J. Kim, H.J. Yoo, H.-J. Lee, J. Kim, C.-R. Jung, K.-S. Chung and M.J. Son 970

## Cholestasis and Autoimmune Diseases

### Obeticholic acid may increase the risk of gallstone formation in susceptible patients

S. Al-Dury, A. Wahlström, K. Panzitt, A. Thorell, M. Ståhlman, M. Trauner, P. Fickert, F. Bäckhed, L. Fändriks, M. Wagner and H.-U. Marschall 986

### Validation, clinical utility and limitations of the Amsterdam-Oxford model for primary sclerosing cholangitis

J.C. Goet, A. Floreani, X. Verhelst, N. Cazzagon, L. Perini, W.J. Lammers, A.C. de Vries, A.J. van der Meer, H.R. van Buuren and B.E. Hansen 992

## Genetic and Metabolic Diseases

### ALDH2 deficiency promotes alcohol-associated liver cancer by activating oncogenic pathways via oxidized DNA-enriched extracellular vesicles

W. Seo, Y. Gao, Y. He, J. Sun, H. Xu, D. Feng, S.H. Park, Y.-E. Cho, A. Guillot, T. Ren, R. Wu, J. Wang, S.-J. Kim, S. Hwang, S. Liangpunsakul, Y. Yang, J. Niu and B. Gao 1000

### Crosstalk between adipose tissue insulin resistance and liver macrophages in non-alcoholic fatty liver disease

C. Rosso, K. Kazankov, R. Younes, S. Esmaili, M. Marietti, M. Sacco, F. Carli, M. Gaggini, F. Salomone, H.J. Møller, M.L. Abate, H. Vilstrup, A. Gastaldelli, J. George, H. Grønbaek and E. Bugianesi 1012

## CLINICAL PRACTICE GUIDELINES

### EASL Clinical Practice Guideline: Occupational liver diseases

M. Colombo 1022

## REVIEW

### Novel classification of non-malignant portal vein thrombosis: A guide to surgical decision-making during liver transplantation

P. Bhangui, C. Lim, E. Levesque, C. Salloum, E. Lahat, C. Feray and D. Azoulay 1038

## LETTERS TO THE EDITOR

### The “six-and-twelve score” for TACE treatment: Does it really help us?

M. Bourlière, G. Pénaranda, X. Adhoute and J.-P. Bronowicki 1051

### Reply to: “The “six-and-twelve score” for TACE treatment: Does it really help us?”

Q. Wang, D. Xia, W. Bai, E. Wang and G. Han 1053

### Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?

B. Hermann, M. Rudler, D. Galanaud, D. Thabut and N. Weiss 1055

### Reply to: “Magnetic resonance spectroscopy: A surrogate marker of hepatic encephalopathy?”

V.A. McLin, O. Braissant and C. Cudalbu 1057

### Canadian liver transplant allocation for hepatocellular carcinoma

M. Brahmania, V. Marquez, N.M. Kneteman, M. Bhat, D. Marleau, P. Wong, K.M. Peletekian, K.W. Burak and S.E. Congly 1058

### Reply to: “Canadian liver transplant allocation for hepatocellular carcinoma”

C. Tschuor, C. Kümmerli, P. Dutkowski, R. Hernandez-Alejandro and P.-A. Clavien 1060

## Registration of Clinical Trials

The *Journal of Hepatology* endorses the policy of the WHO and the International Committee of Medical Journal Editors (ICMJE) on the registration of clinical trials. Therefore, any trial that starts recruiting on or after July 1, 2005 should be registered in a publicly owned, publicly accessible registry and should satisfy a minimal standard dataset. Trials that started recruiting before that date will be considered for publication if registered before September 13, 2005.

More detailed information regarding clinical trials and registration can be found in *New Engl J Med* 2004;351:1250–1251 and *New Engl J Med* 2005;352:2437–2438.

Cover: Donor outcomes in anonymous live liver donation, by Nicolas Goldaracena *et al.* on pp. 951–959 in this issue.

Cover design: Altruism and anonymity in liver donation are represented in this artwork designed by Luciana Giono.